Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes
Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...
Truist Financial Gives a Buy Rating to Jazz Pharmaceuticals (JAZZ)
In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Jazz Pharmaceuticals (JAZZ – Research Report). The ...
Benzinga.com20h
Corcept Therapeutics (NASDAQ:CORT) Stock Quotes, Forecast and News Summary
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast Truist Securities raises the price target for Corcept Therapeutics to $76 ...
Investing19h
Avenue Therapeutics Inc (ATXI)
Avenue Therapeutics, Inc. (NASDAQ:ATXI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an ...
Yahoo Finance13h
Autolus Therapeutics plc (AUTL)
LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies ...